Analyst Ratings For NASDAQ:ICPT – Intercept Pharmaceuticals (NASDAQ:ICPT)
Today, Wedbush lowered its price target on NASDAQ:ICPT – Intercept Pharmaceuticals (NASDAQ:ICPT) to $256.00 per share.
Some recent analyst ratings include
- 3/28/2018-Needham & Company LLC Reiterated Rating of Hold.
- 3/20/2018-Oppenheimer Reiterated Rating of Hold.
- 2/13/2018-Wells Fargo Reiterated Rating of Market Perform.
- 2/12/2018-Deutsche Bank initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:ICPT – Intercept Pharmaceuticals (NASDAQ:ICPT)
NASDAQ:ICPT – Intercept Pharmaceuticals (NASDAQ:ICPT) has insider ownership of 4.50% and institutional ownership of 64.31%.
- On 4/9/2018 Francesco Micheli, Major Shareholder, bought 390,625 with an average share price of $64.00 per share and the total transaction amounting to $25,000,000.00.
- On 4/9/2018 Keith Michael Gottesdiener, Director, bought 1,171 with an average share price of $64.00 per share and the total transaction amounting to $74,944.00.
- On 4/9/2018 Mark Pruzanski, CEO, bought 7,812 with an average share price of $64.00 per share and the total transaction amounting to $499,968.00.
- On 10/2/2017 David Shapiro, CMO, sold 349 with an average share price of $58.90 per share and the total transaction amounting to $20,556.10.
- On 10/2/2017 Mark Pruzanski, CEO, sold 1,532 with an average share price of $58.87 per share and the total transaction amounting to $90,188.84.
- On 10/2/2017 Rachel Mcminn, Insider, sold 283 with an average share price of $58.89 per share and the total transaction amounting to $16,665.87.
- On 10/2/2017 Richard J Kim, SVP, sold 48 with an average share price of $58.10 per share and the total transaction amounting to $2,788.80.
Recent Trading Activity for NASDAQ:ICPT – Intercept Pharmaceuticals (NASDAQ:ICPT)
Shares of NASDAQ:ICPT – Intercept Pharmaceuticals closed the previous trading session at 73.80 down -0.30 0.41% with 74.5999984741211 shares trading hands.